Skip to main content

Advertisement

Table 2 Efficacy of AIT during therapy compared to placebo

From: Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial

Patients AAdSS ± SD
Baseline After 2 years AIT Difference in the adjusted meansa
AIT active; n = 30 4.27 ± 1.58 1.82 ± 0.71 − 3.39
ITT population
AIT placebo; n = 28 4.26 ± 1.6 3.97 ± 0.96 − 0.82
ITT population
AIT active; n = 29 4.34 ± 1.71 1.93 ± 0.64 − 3.51
modified ITT population
AIT placebo; n = 26 4.46 ± 1.69 3.92 ± 1.11 − 0.87
modified ITT population
  1. AAdSS average adjusted symptoms score
  2. aThe differences between AAdSS after 2 years of AIT and baseline